Spontaneous suprachoroidal haemorrhage in haemophilia coincident with ChAdOx1 nCoV-19 vaccine

Behera, Geeta; Jossy, Ajax; Deb, Amit Kumar; Neelakandan, Siddharth; Basavarajegowda, Abhishekh

doi:10.1177/11206721221098207

Cited by 4 publications

(4 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Behera and colleagues reported the case of a 60-year-old male with hemophilia who developed painful and sudden vision loss in his eye a day after receiving ChAdOx1 nCoV-19 (Oxford AstraZeneca) vaccine due to acute angle-closure glaucoma secondary to a massive suprachoroidal hemorrhage. 23 In the other case, a 49-year-old male presented with progressive vision loss one day after administration of the second dose of BNT162b2 vaccine. The patient had a massive intraocular hemorrhage and was diagnosed with secondary angle closure glaucoma, bullous retinal detachment, and massive intraocular hemorrhage.…”

Section: Discussionmentioning

confidence: 99%

Glaucoma cases reported post-COVID-19 vaccination : A VAERS database analysis

Singh

Parmar

Ichhpujani

2022

Preprint

View full text Add to dashboard Cite

Objective: To evaluate glaucoma cases reported post-COVID-19 vaccination and describe the clinical presentations in these cases. Design: An analysis of the Centers for Disease Control and Prevention (CDC) Vaccine Adverse Event Reporting System (VAERS) database Participants: The study includes 161 individuals who were reported for glaucoma after administration of COVID-19 vaccines [BNT162b2 (Pfizer-BioNTech), mRNA-1273 (Moderna) and Ad26.COV2.S (Janssen)] between December 2020 and April 2022. Main Outcome Measures: Estimated crude reporting rate of glaucoma, clinical presentations, onset duration and associated risk factors. Results: A total of 2,061,557,270 doses of COVID-19 vaccines were administered during the study timeframe. During this period, 161 glaucoma cases were reported with an estimated crude reporting rate (per million doses) of 0.09, 0.06 and 0.07 for BNT162b2, mRNA-1273 and Ad26.COV2.S, respectively. The majority of patients (n=130, 80.7%) received BNT162b2, vaccine, while 27 patients (16.8%) received mRNA-1273 and four patients (2.5%) received rAd26.COV2.S vaccines. The mean age of patients in the cohort was 60.41+/-17.56 years and 67.7% (n=109) were women. More than half (56.6%) were reported within the first week after vaccination. The glaucoma onset interval was significantly shorter in patients who received BNT162b2 and rAd26.COV2.S vaccines compared to mRNA-1273 (p=0.013). A higher risk of glaucoma incidence was observed in the short term in patients who received BNT162b2 vaccines compared to mRNA-1273 (p=0.05). In patients vaccinated with mRNA-1273, a significantly higher frequency of glaucoma cases was reported in older patients (p=0.047) compared to younger age groups. Conclusions: The CDC-VAERS data suggest an extremely low safety concern for glaucoma on receiving BNT162b2, mRNA-1273, or Ad26.COV2.S vaccines. The onset interval of adverse events was shorter in patients who received BNT162b2 and rAd26.COV2.S vaccines compared to mRNA-1273. The glaucoma cases after mRNA-1273 vaccination were more commonly reported in older patients. These findings are subject to the limitations of passive reporting systems, under reporting and presumptive case definition, and should be considered preliminary without the medical record analysis for establishing a definitive diagnosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Glaucoma cases reported post-COVID-19 vaccination : A VAERS database analysis

Singh

Parmar

Ichhpujani

2022

Preprint

View full text Add to dashboard Cite

show abstract

“…Additionally, two cases of secondary angle-closure glaucoma post-vaccination have been reported in the literature. Behera and colleagues reported the case of a 60-year-old male with hemophilia who developed painful and sudden vision loss a day after receiving the ChAdOx1 nCoV-19 (Oxford AstraZeneca) vaccine due to acute angle-closure glaucoma secondary to a massive suprachoroidal hemorrhage [ 28 ]. In the other case, a 49-year-old male presented with progressive vision loss one day after the administration of the second dose of the BNT162b2 vaccine.…”

Section: Discussionmentioning

confidence: 99%

Glaucoma Cases Following SARS-CoV-2 Vaccination: A VAERS Database Analysis

et al. 2022

View full text Add to dashboard Cite

Background: To counter the rapidly spreading severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), global vaccination efforts were initiated in December 2020. We assess the risk of glaucoma following SARS-CoV-2 vaccination and evaluate its onset interval and clinical presentations in patients. Methods: We performed a retrospective analysis of the glaucoma cases reported to the Vaccine Adverse Event Reporting System (VAERS) database between 16 December 2020, and 30 April 2022. We assessed the crude reporting rate of glaucoma, clinical presentations, onset duration, and associated risk factors. Results: During this period, 161 glaucoma cases were reported, with crude reporting rates (per million doses) of 0.09, 0.06, and 0.07 for BNT162b2, mRNA-1273, and Ad26.COV2.S, respectively. The mean age of the patients was 60.41 ± 17.56 years, and 67.7% were women. More than half (56.6%) of the cases were reported within the first week of vaccination. The cumulative-incidence analysis showed a higher risk of glaucoma in patients who received the BNT162b2 vaccines compared with mRNA-1273 (p = 0.05). Conclusions: The incidence of glaucoma following vaccination with BNT162b2, mRNA-1273, or Ad26.COV2.S is extremely rare. Amongst the patients diagnosed with glaucoma, the onset interval of adverse events was shorter among those who received the BNT162b2 and rAd26.COV2.S vaccines compared with mRNA-1273. Most glaucoma cases were reported within the first week following vaccination in female patients and from the fifth to seventh decade. This study provides insights into the possible temporal association between reported glaucoma events and SARS-CoV-2 vaccines; however, further investigations are required to identify the potential causality link and pathological mechanisms.

show abstract

“…SCH is also associated with new direct oral anticoagulants such as rivaroxaban and dabigatran, which are alternatives to vitamin K antagonists and heparin and used for thromboembolic diseases and stroke prevention in atrial fibrillation patients [37, 38]. COVID-19 infection or vaccination may be associated with SCH, which can be related to microvascular choroidal changes [39, 40].…”

Section: Spontaneous Schmentioning

confidence: 99%

Suprachoroidal Hemorrhage

Mohan,

Sadeghi,

Mohan

et al. 2023

Ophthalmologica

View full text Add to dashboard Cite

Suprachoroidal hemorrhage (SCH) refers to the accumulation of blood in the suprachoroidal space, a relatively uncommon but significant complication that can occur spontaneously, during ophthalmic surgery or as a consequence of ocular trauma. If left undiagnosed and untreated, SCH can lead to severe vision loss or even blindness. Therefore, it is crucial for ophthalmologists to have a thorough understanding of this complication, taking proactive measures to prevent it during surgery and being knowledgeable about effective management strategies for patients with SCH. This review article aims to provide a comprehensive overview of SCH, covering its risk factors, diagnostic approaches, and the best practices for its management. By enhancing awareness and knowledge in this area, we can improve patient outcomes and minimize the impact of SCH in ophthalmic practice.

show abstract

Spontaneous suprachoroidal haemorrhage in haemophilia coincident with ChAdOx1 nCoV-19 vaccine

Cited by 4 publications

References 7 publications

Glaucoma cases reported post-COVID-19 vaccination : A VAERS database analysis

Glaucoma cases reported post-COVID-19 vaccination : A VAERS database analysis

Glaucoma Cases Following SARS-CoV-2 Vaccination: A VAERS Database Analysis

Suprachoroidal Hemorrhage

Contact Info

Product

Resources

About